Observational studySignal transduction and targeted therapy2021
SARS-CoV-2 immunity and functional recovery of COVID-19 patients 1-year after infection.
Observational study in Signal transduction and targeted therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Long-term evaluation of the seroprevalence of SARS-CoV-2 IgG and IgM antibodies in recovered patients: a meta-analysis.BMC infectious diseases · 2023Pooled it
- One-year follow-up CT findings in COVID-19 patients: A systematic review and meta-analysis.Respirology (Carlton, Vic.) · 2022Pooled it
- Long-Term Consequences of COVID-19 at 6 Months and Above: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Qingjin Yiqi granules for post-COVID-19 condition: A randomized clinical trial.Journal of evidence-based medicine · 2022Trial
- Article
- Risk factors of long COVID among discharged patients with omicron infection in Changzhi, China: a retrospective cohort study.Frontiers in public health · 2026Article
- Severity Matters: How COVID-19 Severity Impacts Long-Term Effects on Symptoms, Physical Activity and Functionality-An Observational Study.Healthcare (Basel, Switzerland) · 2025Article
- Immune responses in COVID-19 patients: Insights into cytokine storms and adaptive immunity kinetics.Heliyon · 2024Review
- Longitudinal analysis of genomic mutations in SARS-CoV-2 isolates from persistent COVID-19 patient.iScience · 2024Article
- Short- and Long-Term Chest-CT Findings after Recovery from COVID-19: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2024Review
- SARS-CoV-2 seroprevalence and associated factors of infection before and after the Delta wave in French Polynesia: a cross-sectional study.BMC public health · 2024Article
- Understanding Patient-Reported Outcome Measures Used in Adult Survivors Experiencing Long-Term Effects After COVID-19 Infection: A Rapid Review.Journal of patient-centered research and reviews · 2024Review
- Systematic Review of the Prevalence of Long COVID.Open forum infectious diseases · 2023Article
- Role of T cells in severe COVID-19 disease, protection, and long term immunity.Immunogenetics · 2023Review
- Review
- Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study.International journal of environmental research and public health · 2023Article
- Long-term Lung Abnormalities Associated with COVID-19 Pneumonia.Radiology · 2023Review
- Cardiovascular Disease in Post-Acute COVID-19 Syndrome: A Comprehensive Review of Pathophysiology and Diagnosis Approach.Reviews in cardiovascular medicine · 2023Review
- Predictors of pulmonary sequelae after COVID-19 pneumonia: A 12-month follow-up study.Frontiers in medicine · 2023Article
- Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients.Scientific data · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 7 institutions in 3 countries.
Funding
Abstract
The long-term immunity and functional recovery after SARS-CoV-2 infection have implications in preventive measures and patient quality of life. Here we analyzed a prospective cohort of 121 recovered COVID-19 patients from Xiangyang, China at 1-year after diagnosis. Among them, chemiluminescence immunoassay-based screening showed 99% (95% CI, 98-100%) seroprevalence 10-12 months after infection, comparing to 0.8% (95% CI, 0.7-0.9%) in the general population. Total anti-receptor-binding domain (RBD) antibodies remained stable since discharge, while anti-RBD IgG and neutralization levels decreased over time. A predictive model estimates 17% (95% CI, 11-24%) and 87% (95% CI, 80-92%) participants were still 50% protected against detectable and severe re-infection of WT SARS-CoV-2, respectively, while neutralization levels against B.1.1.7 and B.1.351 variants were significantly reduced. All non-severe patients showed normal chest CT and 21% reported COVID-19-related symptoms. In contrast, 53% severe patients had abnormal chest CT, decreased pulmonary function or cardiac involvement and 79% were still symptomatic. Our findings suggest long-lasting immune protection after SARS-CoV-2 infection, while also highlight the risk of immune evasive variants and long-term consequences for COVID-19 survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.